Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Prostatic Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Barrett Esophagus 1Advanced Non-small Cell Lung Cancer 1

Interventions

Fluorouracil 155Oxaliplatin 133Leucovorin 124Capecitabine 90Irinotecan 88Radiotherapy 63Bevacizumab 61Cetuximab 38Folfox protocol 25Panitumumab 21Neoadjuvant Therapy 21Surgical Procedures, Operative 19Chemotherapy, Adjuvant 15Radiation 13Floxuridine 13Erlotinib Hydrochloride 13Early Intervention, Educational 13IFL protocol 11Drug Therapy 11Proctectomy 10Magnetic Resonance Spectroscopy 10Counseling 10Surveys and Questionnaires 8Sorafenib 8Psychiatric Rehabilitation 8Gene Expression Profiling 8Radiotherapy, Intensity-Modulated 7Immunohistochemistry 7Gemcitabine 7Celecoxib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Rectal Neoplasms × rofecoxib × Clear all
NCT00031863 2013-08-02

Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡